Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx xxxx a xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Xx. x. x. x x. 46/2008 Xx. x. x.

Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx dne 1. xxxxx 2017 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Seznam xxxxxxxxxx látek x xxxxx xxxxxxx pro xxx 2018 - Xxxxxxxxxxx xxxxxxxx Mezinárodní xxxxxx proti dopingu xx xxxxxx¹⁾.

X novým xxxxxx Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx Xxxxx republiky x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx I vstoupilo x xxxxxxxx x xxxxxxx s článkem 34 xxxx. 3 Xxxxxx xxx 1. ledna 2018. Pro Českou xxxxxxxxx xxxxxxxxx xxxx xxxxx Xxxxxxx I x xxxxxxxx xxx 5. xxxxxx 2019.

Dnem xxxxxx xxxxxx xxxxx Xxxxxxx X v xxxxxxxx přestalo xxxxxx xxxxx Xxxxxxx X xxxxxx od 1. xxxxx 2017 x xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Xxxxxxxx xxxxx nového xxxxx Xxxxxxx X x xxxx překlad xx xxxxxxx jazyka xx xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX XXXXXXXXXXXXX XXXXX

XXXXXX ZAKÁZANÝCH XXXXX X METOD XXXXXXX XXX XXX 2018

MEZINÁRODNÍ XXXXXXXX

Xxxxxxxxx xxxx Xxxxxxx xxxx xxxxxxxxx WADA x xxxx publikován x xxxxxxxxxx a xxxxxxxxxxxxx.

X případě xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx anglická xxxxx.

Xxxxx Seznam bude xxxxxx xx 1. xxxxx 2018 

XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2018

XXXXXXX XXXXXXXXXXXXX KODEX

Platný xx 1. xxxxx 2018

XXXXX X XXXXXX XXXXXXXX STÁLE (PŘI XXXXXXX X MIMO XXXXXX)

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky budou xxxxxxxxxx za "Specifické xxxxx" kromě xxxxx xx xxxxxx X1, X2, X4.4, X4.5 x X6(x) a Xxxxxxxxxx xxxxx M1, X2 a M3.

ZAKÁZANÉ XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxx látka, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx sekcích Xxxxxxx x xxxx aktuálně xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (např. léčiva x preklinickém xxxx xxxxxxxxx stadiu xxxxxxx xxxx po ukončené xxxxxxxxxx, syntetické xxxxx, xxxxx schválené xxxxx xxx veterinární xxxxxxx), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. ANABOLICKÉ XXXXXXXXXX STEROIDY (AAS):

(a) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-diol);

bolasteron;

danazol ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17ß-ol);

drostanolon;

ethylestrenol (19-norpregna-4-en-17α-ol);

fluoxymesteron;

formebolon;

furazabol (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);

metenolon;

methandriol;

metasteron (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9-dien-3-on);

methyl-1-testosteron (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3-on);

trenbolon (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

x. Endogenní** XXX, xxxxx xxxx xxxxxx exogenně:

Androstanolon (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-diol);

19-norandrostendion (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx xxxxxxxxxx x xxxxxxx, xxxxxx, xxx xx s xxxxxxxx xxxxx na ně:

5α-androstan-3α,17α-diol;

5α-androstan-3α,17ß-diol;

5α-androstan-3ß,17α-diol;

5α-androstan-3ß,17ß-diol;

5ß-androstan-3α,17ß-diol;

5α-androst-2-en-17-on;

androst-4-en-3α,17α-diol;

androst-4-en-3α,17ß-diol;

androst-4-en-3ß,17α-diol;

androst-5-en-3α,17α-diol;

androst-5-en-3α,17ß-diol;

androst-5-en-3ß,17α-diol;

4-androstendiol (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx látky, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX, např. xxxxxxx, XXX-4033, xxxxxxx x XXX140); xxxxxxx; xxxxxxx x xxxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.

Xxx účely skupiny xxxx xxxxx: * "exogenní" xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxxxxxx přirozeně xxxxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x látce, xxxxxx xxxx xxxxxxxx xxxxxxxxx produkuje.

S2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx xxxxx a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx, xxxxxx, xxx xx x omezením pouze xx ně:

1.1 Agonisté xxxxxxxxxxxxxxxxx receptoru, xxxx

xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (EPO); xxxxxxxxxx xxxxxxxx xx XXX (EPO-Fc, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA)); XXX-xxxxxxxxx xxxxxxxxxx x jejich xxxxxxxxxx (např. XXXX 530 x xxxxxxxxxxx).

1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx.

xxxxx; kobalt; molidustat; xxxxxxxxxx (XX-4592); xxxxx.

1.3 Xxxxxxxxxx GATA, xxxx.

X-11706.

1.4 Xxxxxxxxxx TGF - xxxx (XXX - β), např.

luspatercept; xxxxxxxxxxx.

1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx. např.

asialo XXX; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx x hormonové xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (XX) x xxxxxxxxxxxx xxxxxx (XX) x xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxx, xxxxxxxxxx, gonadorelin, xxxxxxxxx, xxxxxxxxxxx, nafarelin x triptorelin, u xxxx.

2.2 Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx.

2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxxxx x uvolňující xxxxxxx, včetně, ale xx x omezením xxxxx xx xx:

xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. XXX-9604 a xXX 176-191; xxxxxx xxxxxxxxxx xxxxxxx hormon (XXXX) x jeho analoga, xxxx. XXX-1295, xxxxxxxxxx x tesamorelin; sekretagogy xxxxxxxxx hormonu (XXX), xxxx. xxxxxxx a xxxxxxxx ghrelinu, xxxx. xxxxxxxxxx, xxxxxxxxxx a xxxxxxxxxxx; uvolňující xxxxxxx xxxxxxxxx hormonu (XXXX), xxxx. alexamorelin, GHRP-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, GHRP-5, XXXX-6 x hexarelin.

3. Xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxxxx, xxx xx x xxxxxxxx pouze xx xx:

xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx);

xxxxxxxxxxxx xxxxxxx xxxxxx (XXX);

xxxxxxxx podobný růstový xxxxxx-1 (XXX-1) x xxxx xxxxxxx

xxxxxxxxxx růstové xxxxxxx (MGF);

růstový faktor xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX);

xxxxxxxx- β4 x xxxx xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX).

Xxxxx růstové xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx ovlivňující xxxxxxx xxxx xxxxxxxxx xxxxxxxx svalů, xxxxx x xxxxxx, krevní xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3. BETA2- XXXXXXXX

Xxxxxxx xxxxxxxxxx i neselektivní xxxx-2 xxxxxxxx, xxxxxx xxxxx xxxxxxxxx isomerů, xxxx zakázáni.

Zahrnují (ale xx s xxxxxxxx xxxxx xx xx):

Xxxxxxxxx; xxxxxxxxxx; higenamin; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; salmeterol; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx jsou:

• inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, nepřekračujících 800 xxxxxxxxxx xxxxx xxxxxxx 12 xxxxx xx xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx za 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 mikrogramů xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči x koncentraci vyšší xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxxxxx vyšší než 40 xx/xx xxxxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx nález, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx výsledek xxx způsoben xxxxxxxxxxxxx xxxxxx (x inhalaci) xxxxx, xxx xxxx xxxxxxx maximální xxxxx.

X4. XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx:

1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion);

androsta-3,5-dien-7-17-dion (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, xxx xx x omezením pouze xx xx.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), zahrnující:

Raloxifen;

xxxxxxxxx;

xxxxxxxxx, xxx xx s xxxxxxxx xxxxx na xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:

Cyklofenil;

fulvestrant;

klomifen, xxx xx x xxxxxxxx xxxxx na xx.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; x Xxxxxxxx Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-xxxxxx-4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxxx)xxxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516);

5.2 xxxxxxxx a mimetika xxxxxxxx;

5.3 xxxxxxxxx;

5.4 xxxxxxxxxxxx.

X5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx xxxx xxxxxxxx, xxxxxx xxxx xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; plasmaexpandery (např. xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx); probenecid, xxx xx x xxxxxxxx xxxxx na ně.

• Acetazolamid; xxxxxxxx; bumetanid; furosemid; xxxxxxxxxxxx; indapamid; kanrenon; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, xxxxxxxxxxxxx); xxxxxxxxxx x xxxxxxx (xxxx. tolvaptan), xxx xx x xxxxxxxx xxxxx na xx.

X xxxxxxxx:

• xxxxxxxxxxxx; pamabromu x xxxxxx xxxxxx inhibitorů xxxxxxxxxxxxxx (xxxx. dorzolamidu x xxxxxxxxxxxx)

• Xxxxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx stanoveným xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, metylefedrin x xxxxxxxxxxxxx) xx Vzorku Xxxxxxxxx kdykoliv nebo xxxxxxxx Xxx Xxxxxxx xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx, pokud Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) xx xxxx látku xxxxx x té, xxxxx již byla xxxxxxx xx xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxx.

XXXXXXXX METODY

M1. XXXXXXXXXX X KRVÍ X XXXXXXXX KOMPONENTAMI

Zakázané xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, alogenní (xxxxxxxxx) xxxx xxxxxxxxxxx krve xxxx xxxxxxxxx krvinek x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx systému.

2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx na xxxxxxxxxxx x xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx xx x xxxxxxxx xxxxx xx ně. Inhalační xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo s xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými způsoby.

M2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx xx následující:

1. Xxxxxxxxx, xxxx Xxxxx x Podvod, za xxxxxx porušit xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Dopingové xxxxxxxx. To xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) moči, xxx ne x xxxxxxxx pouze xx xx.

2. Xxxxxxxxxx xxxxxx x/xxxx injekce xxxx xxx xxxxxx 100 xx za 12 xxxxx kromě xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx metod.

M3. XXXXXX XXXXXX

X důvodu xxxxxxxxxx xx zvýšení xxxxxxxxxxx výkonu je xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxx xxxxxxxx nukleových kyselin xxxx xxxxxx xxxxxxx;

2. Xxxxxxx geneticky xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxxx k xxxxxxxxxxx xxxxxxxx xxxxxx x/xxxx x transkripční xxxx xxxxxxxxxxxx regulaci xxxxxx exprese.

3. Xxxxxxx xxxxxxxxxx nebo geneticky xxxxxxxxxxxxxx buněk;

LÁTKY X XXXXXX XXXXXXXX PŘI XXXXXXX

Xxxxx xxxxxxxxx X0 xx X5 x X1 xx X3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx zakázané i xxxxxxxxxxx skupiny:

ZAKÁZANÉ XXXXX

X6. XXXXXXXXXXX

Xxxxxxx stimulancia xxxxxx xxxxx xxxxxx případných xxxxxxxxx xxxxxxx, xxxx. x- x X-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (d-);

mezokarb;

modafinil;

norfenfluramin;

p-metylamfetamin;

prenylamin;

prolintan.

Stimulancium, xxxxx xxxx xxxxxxxx uvedeno x tomto xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (xxx xx x xxxxxxxx xxxxx xx xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (parahydroxyamfetamin);

isomethepten;

katin**;

katinon x xxxx xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx místního/očního xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx xxx 2018*.

* Xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: Tyto xxxxx jsou xxxxxxxx xx Xxxxxxxxxxxxxx programu 2018 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx vyšší xxx 5 mikrogramů v 1 xx moči.

*** Xxxxxxx x xxxxxxxxxxxxx: xxxx xxxxxxxx xxx xxxxxxxxxxx vyšší xxx 10 mikrogramů x 1 xx xxxx.

**** Xxxxxxxxx (epinefrin): xxxx xxxxxxx xxx xxxxxxxx xxxxxx, např. xxxxx, xxxx xxxxxxxx nebo xxxx podání xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

***** Xxxxxxxxxxxxx: je xxxxxxx, xxxxx xxxx xxxxxxxxxxx x moči xx xxxxx xxx 150 xxxxxxxxxx xx mililitr.

S7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx x jeho xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx:

• Xxxxxxxx kanabinoidy, xxxx. hašiš, xxxxxx x marihuana.

• Syntetické xxxxxxxxxxx, xxxx. delta9-tetrahydrokanabinol (XXX) x xxxxxxx xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx glukokortikoidy xxxxxxxx orálně, rektálně, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.

Xxxxxx, xxx ne s xxxxxxxx xxxxx xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX ZAKÁZANÉ V URČITÝCH XXXXXXXX

X1. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx, x xxx xx xx označeno x Xxxx xxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx lyžování-skoky x X-xxxxx, x xxxxxxxxx X-xxxxx a "xxx xxx"

• Xxxxxxxx xxxxxx (xxxxxxxxx xxxxxxxx) (CMAS) x disciplínách xxxxxxxxxx xxxx s xxxxxxxxx xxxx xxx xxxxxxx, xxxxxxxxx apnoe x xxxxxxxxx nebo xxx xxxxxxx, xxxx immersion, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx xx terč x variabilní váha.

• Střelba (XXXX, XXX)*

• Xxxxx (WDF)

* Xxxxxxxx také Mimo xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx ne x xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 36/2019 Xx. x. x. xxxxx xxxxxxxxx xxxx 26.7.2019.

Xxxxxx předpis x. 36/2019 Sb. x. x. byl xxxxxx právním xxxxxxxxx č. 32/2023 Sb. m. s. s účinností xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx předpisů x xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx xxxxxx xxxxxxxxx změna xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Xxxxxxxxxxx úmluva xxxxx xxxxxxx xx xxxxxx, xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx, byla xxxxxxxxx x xxxxxxxxx xxxxx a s xxxxxxxxx xx xxxxxxx xxxxxx xxx č. 58/2007 Sb. m. s.

Xxxx xxxxx xxxxxxxx Úmluvy xx xxxxxxx xxxxxx xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.